<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated the frequency of p53 mutations in 19 pediatric cases of therapy-related <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Eleven children presented with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, one with mixed-lineage <z:hpo ids='HP_0001909'>leukemia</z:hpo>, two with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>, and five with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> at times ranging from 11 months to 9 years after a primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis </plain></SENT>
<SENT sid="2" pm="."><plain>The primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, which included 11 solid <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and eight <z:hpo ids='HP_0001909'>leukemias</z:hpo>, were treated with various combinations of DNA <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi>, <z:chebi fb="0" ids="22333">alkylating agents</z:chebi>, or irradiation </plain></SENT>
<SENT sid="3" pm="."><plain>Leukemic or myelodysplastic marrows were screened for possible mutations by single-strand conformation polymorphism (SSCP) analysis of p53 exons 4 to 8 </plain></SENT>
<SENT sid="4" pm="."><plain>The only observed mutation was an inherited 2-basepair deletion at codon 209 in exon 6 that would shift the open reading frame, create a premature termination codon, and foreshorten the resultant protein </plain></SENT>
<SENT sid="5" pm="."><plain>Prior therapy in this patient included DNA <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi>, <z:chebi fb="0" ids="22333">alkylating agents</z:chebi>, and irradiation </plain></SENT>
<SENT sid="6" pm="."><plain>The secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> presented as <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> with <z:mp ids='MP_0004026'>monosomies</z:mp> of chromosomes 5 and 7 and abnormalities of chromosome 17 </plain></SENT>
<SENT sid="7" pm="."><plain>Although the primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was an <z:hpo ids='HP_0006743'>embryonal rhabdomyosarcoma</z:hpo> and there was a family history of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, the case did not fulfill the clinical criteria for <z:e sem="disease" ids="C0085390" disease_type="Neoplastic Process" abbrv="LFS">Li-Fraumeni syndrome</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>This study suggests that germline p53 mutations may predispose some children to therapy-related <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, but that p53 mutations otherwise are infrequent in this setting </plain></SENT>
</text></document>